title: Transgenic mouse overexpressing the Akt reduced the volume of infarct area after middle cerebral artery occlusion.
abstract: Transgenic mouse lines expressing the active form Akt gene under the control of the damage-induced neuronal endopeptidase (DINE) promoter were made from three different founder mice, and its neuroprotective potential against ischemic brain damage was investigated. Twenty-four hours after middle cerebral artery occlusion, two DINE-Akt-transgenic mouse lines displayed reductions of the infarcted area by 35% compared to the wild-type littermate. RT-PCR assays showed a high level of transgene in response to ischemic brain damage in these lines. These results suggest that the DINE promoter is a useful promoter, which responds to neuronal insults and that the Akt-induced neuroprotective effect against ischemic damage is potent in vivo.
authors.affiliation: Department of Anatomy and Neurobiology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.
authors.forename: Norihiro
authors.initials: N
authors.lastname: Ohba
authors.forename: Sumiko
authors.initials: S
authors.lastname: Kiryu-Seo
authors.forename: Mitsuyo
authors.initials: M
authors.lastname: Maeda
authors.forename: Michinari
authors.initials: M
authors.lastname: Muraoka
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Ishii
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kiyama
mesh_terms: D000818:Animals; D002544:Cerebral Infarction / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D005240:Feasibility Studies; D024861:Genetic Enhancement / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D020244:Infarction, Middle Cerebral Artery / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D051379:Mice / Q000235:genetics / Q000378:metabolism; D008822:Mice, Transgenic / Q000235:genetics; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt; D011994:Recombinant Proteins / Q000378:metabolism; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D011518:Proto-Oncogene Proteins; D011994:Recombinant Proteins; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt